Implications of deranged activated partial thromboplastin time for anaesthesia and surgery

被引:21
作者
Loizou, E. [1 ]
Mayhew, D. J. [2 ,3 ]
Martlew, V. [4 ]
Murthy, B. V. S. [4 ,5 ]
机构
[1] St Helens & Knowsley NHS Fdn Trust, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Univ Liverpool, Liverpool, Merseyside, England
[4] Royal Liverpool & Broadgreen Univ Hosp Trust, Liverpool, Merseyside, England
[5] Liverpool John Moores Univ, Anaesthesia, Liverpool, Merseyside, England
关键词
antithrombotic drugs: pre-operative management; indications LMWH; pre-operative management; DIRECT ORAL ANTICOAGULANTS; CRITICALLY-ILL PATIENTS; FACTOR-VIII INHIBITOR; LUPUS ANTICOAGULANT; UNFRACTIONATED HEPARIN; PROTHROMBIN TIME; SCREENING-TESTS; PRACTICAL GUIDE; COAGULATION; MANAGEMENT;
D O I
10.1111/anae.14344
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Bleeding during and after surgery ranges from trivial to fatal. Bleeding is in part determined by the patient's coagulation status. The UK National Institute for Health and Care Excellence recommends a pre-operative clotting test for patients with a history of abnormal bleeding. Anaesthetists are familiar with the prothrombin time assay, used to monitor warfarin effect, but anaesthetists may be less familiar with the activated partial thromboplastin time (APTT), which tests the function of the 'intrinsic' clotting pathway. The activated partial thromboplastin time may be prolonged due to contamination, anticoagulant therapy, clotting factor deficiencies, lupus anticoagulant or acquired inhibitors of specific clotting factors. A prolonged activated partial thromboplastin time should lead to: further testing to exclude heparin contamination or therapy, mixing studies to identify factor deficiencies and if necessary dynamic studies, such as the dilute Russell's viper venom time and the Actin FS-activated partial thromboplastin time, to identify direct factor inhibitors. These tests identify abnormalities and their implications for bleeding, helping anaesthetists and haematologists to manage haemostasis for individual patients.
引用
收藏
页码:1557 / 1563
页数:7
相关论文
共 44 条
[1]  
Aarab R, 2013, NETH J MED, V71, P466
[2]   Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review [J].
Adcock, D. M. ;
Gosselin, R. .
THROMBOSIS RESEARCH, 2015, 136 (01) :7-12
[3]   The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran [J].
Alikhan, Raza ;
Rayment, Rachel ;
Keeling, David ;
Baglin, Trevor ;
Benson, Gary ;
Green, Laura ;
Marshall, Scott ;
Patel, Raj ;
Pavord, Sue ;
Rose, Peter ;
Tait, Campbell .
EMERGENCY MEDICINE JOURNAL, 2014, 31 (02) :163-168
[4]   Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant [J].
Ames, Paul R. J. ;
Graf, Maria ;
Archer, Jeremy ;
Scarpato, Nicola ;
Iannaccone, Luigi .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (02) :149-154
[5]  
[Anonymous], J HEMATOL TRANSFUS
[6]  
Bain BJ, 2017, DACIE LEWIS PRACTICA, V12th, P238
[7]  
Ceresetto JM, 2015, MEDICINA-BUENOS AIRE, V75, P231
[8]   Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures [J].
Chee, Y. L. ;
Crawford, J. C. ;
Watson, H. G. ;
Greaves, M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (05) :496-504
[9]   Coagulation [J].
Chee, Y. L. .
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2014, 44 (01) :42-45
[10]  
Chee Yen-Lin, 2003, Hematol J, V4, P373, DOI 10.1038/sj.thj.6200306